Consistent with our findings,a pharmacovigilance study revealed that anti-BCMA BsAbs were linked to a 2-fold rise in the risk of infectious complications relative to other MM treatments (42). The gene discussed is TNFRSF17; the disease is Miyoshi myopathy.